https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36361 Wed 24 May 2023 12:19:20 AEST ]]> Paradoxical metastatic progression following 3 months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18510 Wed 11 Apr 2018 14:04:35 AEST ]]> Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30211 Wed 09 Feb 2022 15:53:54 AEDT ]]> It's time to depolarise the unhelpful PSA-testing debate and put into practice lessons from the two major international screening trials https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:10956 Sat 24 Mar 2018 08:14:14 AEDT ]]> Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21389 Sat 24 Mar 2018 08:05:04 AEDT ]]> Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21390 p< 0.001) in urinary dysfunction were measured using the EORTC PR25 instrument at 18 and 36 months. Conclusion: Adjuvant androgen suppression, bisphosphonates and increasing EBRT dose did not increase rectal or urinary dysfunction in this trial. However dose escalation using HDRB increased urinary dysfunction.]]> Sat 24 Mar 2018 08:05:03 AEDT ]]> AST-induced bone loss in men with prostate cancer: exercise as a potential countermeasure https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20435 Sat 24 Mar 2018 08:03:22 AEDT ]]> Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22823 Sat 24 Mar 2018 07:16:10 AEDT ]]> A randomised trial investigating the effect on biochemical (PSA) control and survival of different durations of adjuvant androgen deprivation in association with definitive radiation treatment for localised carcinoma of the prostate https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33247 7 cutpoint identified in 2014 for the BP and STI endpoints. A tertiary objective of the trial is to determine whether intercurrent medical conditions will impact independently on delayed radiotherapy morbidity and other treatment related morbidity.]]> Mon 23 Sep 2019 13:37:53 AEST ]]>